VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Novel agents for MDS on the basis of understanding disease biology

Myelodysplastic syndromes (MDS) represent a clinically heterogeneous group of disorders with challenging unmet therapeutic needs. At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses emerging agents for the treatment of patients with MDS, including transforming growth factor-beta inhibitors, thrombopoietic agents and targets of mutant IDH2.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter